Opinion|Videos|May 1, 2026
Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic
This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Episodes in this series
This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
Related Content
Latest CME
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
Higher saturated fat intake associated with increased mortality in nonmetastatic prostate cancer
3
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
4
FDA reports increased demand, supply efforts for estradiol transdermal patches
5